ATE382332T1 - Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid - Google Patents
Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochloridInfo
- Publication number
- ATE382332T1 ATE382332T1 AT05774341T AT05774341T ATE382332T1 AT E382332 T1 ATE382332 T1 AT E382332T1 AT 05774341 T AT05774341 T AT 05774341T AT 05774341 T AT05774341 T AT 05774341T AT E382332 T1 ATE382332 T1 AT E382332T1
- Authority
- AT
- Austria
- Prior art keywords
- dissolution
- buffer
- tamsulosin hydrochloride
- controlled release
- release formulation
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 title 1
- 238000004090 dissolution Methods 0.000 abstract 4
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical group Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 abstract 3
- 229960003198 tamsulosin hydrochloride Drugs 0.000 abstract 3
- 239000000872 buffer Substances 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000009506 drug dissolution testing Methods 0.000 abstract 1
- 239000002662 enteric coated tablet Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL369566A PL204079B1 (pl) | 2004-08-12 | 2004-08-12 | Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE382332T1 true ATE382332T1 (de) | 2008-01-15 |
Family
ID=35445840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05774341T ATE382332T1 (de) | 2004-08-12 | 2005-08-12 | Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070298101A1 (de) |
| EP (1) | EP1784161B1 (de) |
| AT (1) | ATE382332T1 (de) |
| DE (1) | DE602005004164T2 (de) |
| PL (2) | PL204079B1 (de) |
| SI (1) | SI1784161T1 (de) |
| WO (1) | WO2006016829A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722458B2 (en) * | 2011-12-02 | 2020-07-28 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
| JP2015500241A (ja) * | 2011-12-02 | 2015-01-05 | ペガサス ラボラトリーズ インコーポレイテッド | 両親媒性脂質をベースとする徐放性組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8528195D0 (en) * | 1985-11-15 | 1985-12-18 | Boots Co Plc | Therapeutic compositions |
| IT1289160B1 (it) * | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| JP4019374B2 (ja) * | 2001-07-27 | 2007-12-12 | アステラス製薬株式会社 | 口腔内速崩壊錠用徐放性微粒子含有組成物およびその製造法 |
| JP2005512997A (ja) * | 2001-11-07 | 2005-05-12 | シントン・ベスローテン・フェンノートシャップ | タムスロシン錠 |
-
2004
- 2004-08-12 PL PL369566A patent/PL204079B1/pl not_active IP Right Cessation
-
2005
- 2005-08-12 SI SI200530197T patent/SI1784161T1/sl unknown
- 2005-08-12 PL PL05774341T patent/PL1784161T3/pl unknown
- 2005-08-12 DE DE602005004164T patent/DE602005004164T2/de not_active Expired - Lifetime
- 2005-08-12 WO PCT/PL2005/000052 patent/WO2006016829A1/en not_active Ceased
- 2005-08-12 US US11/573,562 patent/US20070298101A1/en not_active Abandoned
- 2005-08-12 AT AT05774341T patent/ATE382332T1/de not_active IP Right Cessation
- 2005-08-12 EP EP05774341A patent/EP1784161B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PL1784161T3 (pl) | 2008-05-30 |
| WO2006016829A1 (en) | 2006-02-16 |
| EP1784161B1 (de) | 2008-01-02 |
| DE602005004164D1 (de) | 2008-02-14 |
| PL204079B1 (pl) | 2009-12-31 |
| US20070298101A1 (en) | 2007-12-27 |
| DE602005004164T2 (de) | 2008-12-11 |
| SI1784161T1 (sl) | 2008-06-30 |
| EP1784161A1 (de) | 2007-05-16 |
| PL369566A1 (pl) | 2006-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kranz et al. | Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug | |
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| ES2758831T3 (es) | Nuevas y potentes formas de dosificación de tapentadol | |
| AU2013344281B2 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| ES2642788T3 (es) | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos | |
| Liu et al. | Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system | |
| JP2009538918A (ja) | フェニレフリンを含有する徐放薬学的投薬形態 | |
| HRP20041234B1 (hr) | Oblik pramipeksola za doziranje jednom dnevno | |
| US10258584B2 (en) | Pregabalin sustained-release preparation | |
| TWI638657B (zh) | 多西拉敏及吡哆醇及/或其代謝物或鹽之調配物 | |
| SE1251371A1 (sv) | Farmaceutiska kompositioner innefattande hydromorfon och naloxon | |
| US20210290550A1 (en) | Process for Preparing Rapidly or Very Rapidly Dissolving Tablets Comprising Freely Soluble API | |
| AU2012326976B2 (en) | Sustained-release preparation | |
| Kranz et al. | Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug | |
| KR20230080461A (ko) | 약학적 제형 | |
| US20080138411A1 (en) | Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors | |
| US20100003322A1 (en) | Enteric coated hydrophobic matrix formulation | |
| KR101464053B1 (ko) | 4-메틸피라졸 배합물 | |
| RU2018137590A (ru) | Фармацевтические композиции для производного n-пропаргиламина | |
| ATE382332T1 (de) | Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid | |
| CN105492013B (zh) | 用于管理恶心和呕吐的组合物 | |
| US20150148388A1 (en) | Chemical composition | |
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| CN104853752A (zh) | 嘧啶二酮衍生物化合物的制剂 | |
| EP1628642B1 (de) | Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |